X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Blood Vessel Route- Major Discovery In Alzheimers Treatment

Content Team by Content Team
21st June 2022
in Manufacturing, Middle East and South Asia, News
Blood Vessel Route- Major Discovery In Alzheimers Treatment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

As per University of Manchester studies funded by the British Heart Foundation (BHF) and published in Proceedings of the National Academy of Sciences, a significant development in the understanding of Alzheimer’s disease has put forth changes to blood vessels in the brain, ideally presenting a way for developing new drugs that help fight the disease.

Alzheimer’s is typically considered to be a brain disorder in which a protein called Amyloid-beta accumulates and forms plaques in the brain cells. There is mounting evidence that the brain’s blood supply is also harmed; however, how this occurs is uncertain. Researchers at the University of Manchester have discovered that a smaller version of the protein known as Amyloid-β 1-40 accumulates in the walls of tiny arteries and restricts blood flow to the brain.

The cortex of the brain is covered with tiny arteries known as pial arteries, which regulate the flow of blood and oxygen to the brain. The brain cannot acquire adequate nourishment if these arteries are restricted over an extended period of time. This is one of the reasons for memory loss in Alzheimer’s patients.

When the researchers examined the pial arteries of older mice with Alzheimer’s disease that produced too much A1-40, they discovered that they were narrower than those of healthy mice.

The narrowing was discovered to be triggered by A1-40 turning off a specific protein BK in blood vessel cells. When BK is in good working order, it sends out a signal that induces arteries to expand. Researchers immersed healthy pial arteries in A 1-40 and examined the impulses sent by the BK protein after an hour to confirm that A 1-40 blocked BK from working properly. These signals were weakened by A1-40, causing the arteries to constrict.

The researchers will now examine which components of A1-40 inhibit the BK protein so that medications to prevent this can be produced and evaluated as a much-needed therapy to halt the progression of Alzheimer’s disease and spare individuals the agony of losing their memories. To date, approximately 500 medications have been trialled as a cure for Alzheimer’s disease, said the lead BHF-funded researcher and Clinical Senior Lecturer in Cardiovascular Sciences at the University of Manchester, Dr Adam Greenstein. All have tried to target the nerves in the brain, but none of them have succeeded. They have opened up new areas of inquiry to identify an effective cure for Alzheimer’s disease by revealing how the disease affects small blood vessels.

This research is a major step forward in the understanding of Alzheimer’s disease, said Associate Medical Director of the British Heart Foundation, Professor Metin Avkiran. Well over half a million individuals in the UK suffer from the disease, and the figure is expected to climb as the population ages. These discoveries could contribute to a much-needed cure for this life-threatening disease.

Previous Post

Valneva, A French Vaccines Firm To Sell 8.1% Share To Pfizer

Next Post

Stanford Builds Amphibious Millirobot That Manoeuvre On Trip

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Stanford Builds Amphibious Millirobot That Manoeuvre On Trip

Stanford Builds Amphibious Millirobot That Manoeuvre On Trip

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In